A phase 2 clinical trial has delivered some of the most striking results yet reported in early-stage classical Hodgkin ...
Circulating tumor DNA predicts recurrence and splits disease into two subgroups of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity. A Stanford Medicine-led, ...
Hosted on MSN
Surviving Hodgkin lymphoma may leave you at double the long-term mortality risk, even years later
Adults who beat Hodgkin lymphoma and made it past the five-year mark still died at nearly twice the rate expected for the general US population, according to a new analysis of more than 20,000 ...
Hodgkin's lymphoma (HL), impacting the lymph nodes and lymphatic system, has experienced a gradual increase in survival rates thanks to contemporary chemotherapy. However, challenges persist for ...
Twenty-five years after Hodgkin lymphoma treatment at what is now Atrium Health Levine Cancer, television and awards show ...
Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen. This is compared to 83% ...
Adults who have survived Hodgkin lymphoma (HL) for at least five years face significantly elevated long-term health risks, according to a new study led by researchers at The University of Texas MD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results